VERA
NASDAQVera Therapeutics Inc.
Price$31.61-0.93 (-2.84%)
01:30 PM07:45 PM
News · 26 weeks70+71%
2025-12-142026-06-07
Mix3090d
- Insider13(43%)
- Other10(33%)
- SEC Filings6(20%)
- Leadership1(3%)
Latest news
25 items- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stoc
- SECVera Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyPrescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027Pending positive eGFR analysis, plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026, with potential full approval in 2027 BRISBANE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it has aligned with the U.S. Food and Drug
- SECVera Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- INSIDERSEC Form 4 filed by Director Morrison Scott W4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Cheng Andrew4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Seidenberg Beth C4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Oliger Christy J.4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Meyers James R4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Hall Kimball4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Morrissey Michael4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- INSIDERSEC Form 4 filed by Director Enright Patrick G4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vera Therapeutics Inc.SCHEDULE 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
- INSIDERPRESIDENT AND CEO Fordyce Marshall sold $679,747 worth of shares (18,500 units at $36.74) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 216,744 units (SEC Form 4)4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock op
- SECSEC Form 10-Q filed by Vera Therapeutics Inc.10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECVera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
- PRVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approvalStrong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch BRISBANE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological
- PRVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceBRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings. Presentation Details:Date: Wednesday, May 13, 2026 Time: 4:20 PM PDT Webcast: https://bofa.veracast.com/webcasts/bofa/healthcare2026/24Ty86.cfm A replay of the event will be available for 90 days and c
- INSIDERSEC Form 4 filed by Fordyce Marshall4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- SECSEC Form DEFA14A filed by Vera Therapeutics Inc.DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECSEC Form DEF 14A filed by Vera Therapeutics Inc.DEF 14A - Vera Therapeutics, Inc. (0001831828) (Filer)
- SECSEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
- PRVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera's new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq List
VERA FAQ
7 questionsWhat does Vera Therapeutics Inc. do?
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco...Where does VERA stock trade?
Vera Therapeutics Inc. (VERA) is listed on NASDAQ.What sector and industry is VERA in?
Vera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vera Therapeutics Inc. go public?
Vera Therapeutics Inc. (VERA) completed its IPO in 2021.What are analysts saying about VERA?
Vera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-03-11. Recent price targets range from $4800.00 to $4900.00.What companies are similar to VERA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VERA side-by-side with any of them on Quantisnow.How can I track VERA on Quantisnow?
Quantisnow aggregates Vera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VERA to receive live email and push alerts on every new disclosure.